Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Envista (NVST)

Envista Adds J. Andrew Pierce to Board, Expanding It to Nine Members

Neutral Impact 3 of 5 leadership Written later

Envista Holdings elected J. Andrew Pierce, Group President of Stryker's MedSurg & Neurotechnology group, to its board effective July 14, 2025, increasing the board from eight to nine members. He also joined the Audit Committee, which the board determined he is independent to serve on.

Key points

  • Pierce elected to the board effective July 14, 2025, with a term running until the 2026 Annual Meeting of Stockholders
  • Board increased from eight members to nine
  • Pierce joined the Audit Committee; the committee now includes Ms. Tsingos (Chair), Mr. Huennekens and Mr. Pierce
  • He will receive a pro-rated standard annual retainer for the rest of fiscal 2025, plus director equity awards and expense reimbursement

The filing

CompanyEnvista (NVST)
Form8-K, current report
Filed with the SECJul 16, 2025, 4:12 PM ET
Accession number0001757073-25-000036

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 16, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.